Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.

Also called NCT07282041

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 2/3
Enrolled
  • 130 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07282041
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Singapore (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07282041. Randomized; single masking; primary purpose prevention. Start 2025-12-17 (actual); primary completion 2030-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis
Acronym
RADIANT
Condition
Intracranial Atherosclerosis
Condition
Stroke, Ischemic
Intervention (Drug)
Dulaglutide
Lead sponsor
National University of Singapore (class: other)

Record details

Record id
cardio:ct-nct07282041
Content hash
6d2ea1de88b84e2609853f5fc30e55e786bd453e265e59114c478ac8522c847c